SIC
RIGL icon

SJS Investment Consulting’s Rigel Pharmaceuticals RIGL Stock Holding History

SJS Investment Consulting’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$28 Sell
1
-3
-75% -$101 ﹤0.01% 2340
2025
Q4 		$172 Buy
+4
New +$151 ﹤0.01% 1845

Other funds holding RIGL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SJS Investment Consulting's RIGL Position: Q1 2026 in Review

SJS Investment Consulting reduced its Rigel Pharmaceuticals (RIGL) stake by 75% in Q1 2026, selling an estimated $101 and leaving 1 share worth $28. The position accounts for ﹤0.01% of the portfolio, ranked #2340.

SJS Investment Consulting first reported a position in RIGL in Q4 2025 and has held it in 2 quarters since. The position peaked at $172 in Q4 2025. 159 funds tracked by Wall St. Rank hold RIGL as of Q1 2026.

  • SJS Investment Consulting held 1 share of Rigel Pharmaceuticals worth $28 as of Q1 2026.
  • SJS Investment Consulting sold 3 Rigel Pharmaceuticals shares in Q1 2026, an estimated $101.
  • Rigel Pharmaceuticals made up ﹤0.01% of SJS Investment Consulting's portfolio in Q1 2026, its #2340 holding.
  • SJS Investment Consulting first reported a position in Rigel Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • SJS Investment Consulting's Rigel Pharmaceuticals position peaked at $172 in Q4 2025.
  • 159 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2026.

Based on SJS Investment Consulting's 13F filing for Q1 2026, filed 23 Apr 2026.